A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Peter Schmid, Marie Paule Sablin, Jonas Bergh, Seock Ah Im, Yen Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa Maria Espadero, Thomas Bogenrieder, Dennis Chin Lun Huang, John Crown, Javier Cortés

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences